In contrast with this observation, others indicate that intra-cellular trafficking of EGFR is enhanced by Cetuximab [26] and there is a wide literature correlating poor response to Cetuximab with EGFR nuclear localization thus making nuclear EGFR an important molecular target in cancer [27–29]. This evidence concerns the gene EGFR and cancer.